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物呈现良好的抑制肿瘤细胞生长活性的作用，例如化合物 ZMY-15 和 ZMY-23，
其 IC50 值分别为 3.38 μM和 4.46 μM。其中 ZMY-15对 HepG2细胞显示出良好
的抑制活性。我们发现，ZMY-15 能够明显抑制 HIF-1α 蛋白水平的表达，抑制
HepG2细胞 HIF-1α靶基因 EPO及 VEGF mRNA水平的表达从而促进肿瘤细胞
的凋亡，抑制其恶性增殖。本研究结果表明含哌嗪环的类黄酮化合物 ZMY-15





















Hypoxia microenvironment is common exist in tumor cells, HIF-1α plays a key 
role in the process that tumor cells adapt to hypoxia environment, if the drug can 
inhibit the activity of HIF-1α, that also can inhibited the tumor cells to adapt to 
hypoxia Environment, and then can inhibit the growth of the tumor cells. HIF-1α is 
also involved in the occurrence of tumor cells, progression and metastasis. Therefore, 
more and more scientific researchers regard HIF-1α as a target to develop a series of 
HIF-1α inhibitors, in order to achieve the role of anti-tumor. 
In recent years, the relationship between the anti-tumor activity of the flavonoid 
compounds and HIF-1 is gradually being revealed, but the related research is still less. 
The further research of the relationship between flavonoids and HIF-1 in anti-tumor 
activity can provide new ideas for the development of new antitumor compounds.In 
this paper, we use the natural products of baicalein and genistein as the lead 
compound, through the bio-electronic isotope theory, pharmacokinetics and other 
drug molecular design theory, design and synthesiz two series of 41 new piperazine 
ring containing flavonoid compounds . All of the synthetic chemicals were confirmed 
by nuclear magnetic resonance spectroscopy, nuclear magnetic resonance 
spectroscopy and mass spectrometry. In order to improve the lipid partition 
coefficient of the drug, a piperazine ring was add to the structural modification. 
Through the preliminary screening of the inhibition of proliferation activity of 
HepG2 cells, we found that some of these derivatives showed a good inhibitory effect 
on growth activity of tumor cell. For example, compounds ZMY-15 and ZMY-23 ，
the IC50 were 3.38 μM and 4.46 μM, respectively. Wherein ZMY-15 shows good 
inhibitory activity against HepG2 cells. We found that ZMY-15 significantly 
inhibited the expression of HIF-1α protein and inhibited the expression of HIF-1α 
target gene EPO and VEGF mRNA in HepG2 cells, thus promoting the apoptosis of 
tumor cells and inhibiting its malignant proliferation. The results show that the 
flavonoid compound ZMY-15, which contains piperazine ring, promotes the 
apoptosis of tumor cells by inhibiting the expression of hypoxia-inducible factor HIF-















In this paper, the new compound ZMY-15, which is a structural compound 
optimized by using the natural compound baicalein and genistein as the lead 
compound, provides an important research basis for the design of anti-tumor targeting 
drug. Those compounds have application prospects, and the further research about the 
anti-tumor mechanism is in progress. 

















SAR Structure activity relationships 构效关系 
VEGF Vascular Endothelial Growth Factor 血管内皮生长因子 
AMPK 
Adenosine Mono-hosphate Activated 
Protein Kinase 
腺苷酸活化蛋白激酶 
EGF Epidermal Growth Factor 内皮生长因子 
EGFR Epidermal Growth Factor Receptor 内皮生长因子受体 
HIF Hypoxia Inducible Factor 缺氧诱导因子 
TAD Transactivation Domain 反式激活区 
ODDD Oxygen-Dependent-Degradation Domain 氧依赖性降解结构 
pVHL Von Hippel Lindau protein 希佩尔林道病肿瘤抑制蛋白 
PI3K Phosphatudylinositol 3-Kinase 磷脂酰肌醇-3激酶 
sGC Soluble guanylate cyclase 可溶性鸟甘酸环化酶 
PHD Prolyl Hydroxylases Domain-containing  
Protein 
脯氨酸氢化酶 
AKT Protein kinase B 蛋白激酶 B 
HDAC Histone deacetylase 组蛋白脱乙酰基酶 
DMF N,N-Dimethylformamide 氮氮二甲基甲酰胺 
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